114 results
Page 2 of 6
6-K
EX-99.1
b8yjs4n
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
a1siz7vihou
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
whj60
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
ca4dz ajg7qukf
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
F-3
EX-4.1
71k6unh
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
he8l9lx3p0
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
hmimex
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
8p6cq bh56
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
EX-99.3
m6sdfb30yxp9vqff9db
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
EX-99.1
8ofu8xi7e9do 3nek
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
ucorchv 4m4
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
kig9t 6dcih
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
ptc 6ooug069
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
booh behq
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
8w2nq921
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
fkhkm etk
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
jft79y03zdyuoadlsk1
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
k84553fk
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm